Cite
HARVARD Citation
Feagan, B. et al. (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet gastroenterology and hepatology. pp. 307-320. [Online].